Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer

Clinical Lung Cancer

Volumn 9, Issue 5, 2008, Pages 285-287

  Nanda, Akash ^a,b   Dias Santagata, Dora C ^b   Stubbs, Hannah ^b   O'Hara, Carl J ^a   Zaner, Ken S ^a   Lynch, Thomas J ^b   Willers, Henning ^a,b  

^a BOSTON MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Epidermal growth factor receptor; Molecular targeted radiation therapy; S768I; Tyrosine kinase inhibitor

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PACLITAXEL; STEROID;

ADULT; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION PNEUMONIA; TREATMENT RESPONSE;

EID: 54249097770     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.044     Document Type: Article

References (14)

1. Chen YR, Fu YN, Lin CH, et al. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 2006; 25:1205-15.
2. Asahina H, Yamazaki K, Kinoshita I, et al. Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 2006; 54:419-22.
3. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell cancer: first analysis of a randomized trial in 353 patients. J Nat Cancer Inst 1991; 83:417-23.
4. Penland SK, Socinski MA. Management of unresectable stage III non-small cell lung cancer: The role of combined chemoradiation. Semin Radiat Oncol 2004; 14:326-34.
5. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small cell lung cancer. J Clin Oncol 2005; 23:3257-69.
6. Arteaga CL. ErbB-targeted rherapeutic approaches in human cancer. Exp Cell Res 2003; 284:122-30.
7. Schmidt-Ullrich RK, Contessa JN, Lammering G, et al. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 2003; 22:5855-65.
8. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007; 25:4057-65.
9. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999; 45:323-9.
10. Wu KL, Jiang GL, Qian H, et al. Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial. Int J Radiat Oncol Biol Phys 2003; 57:1345-50.
11. Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 2006; 23:161-70.
12. Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007; 357:514-5.
13. Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Ann Rev Med 2008; 59:429-42.
14. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.